Is Natera, Inc. (NTRA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.7% / 30% | 3.4% / 30% | 1.1% / 30% | 2.55% / 5% | ✓ HALAL |
| DJIM | 0.7% / 33% | 3.4% / 33% | 1.1% / 33% | 2.55% / 5% | ✓ HALAL |
| MSCI | 11.3% / 33% | 58.3% / 33% | 18.9% / 33% | 2.55% / 5% | ✗ NOT HALAL |
| S&P | 0.7% / 33% | 3.4% / 33% | 1.1% / 33% | 2.55% / 5% | ✓ HALAL |
| FTSE | 11.3% / 33% | 58.3% / 33% | 18.9% / 50% | 2.55% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 64.7% | |
| Operating Margin | -3.4% | |
| Net Margin | -9.0% | |
| Return on Equity (ROE) | -14.3% | |
| Return on Assets (ROA) | -9.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $215M |
| Free Cash Flow | $76M |
| Total Debt | $214M |
| Debt-to-Equity | 12.5 |
| Current Ratio | 3.4 |
| Total Assets | $2.4B |
Price & Trading
| Last Close | $196.15 |
| 50-Day MA | $211.69 |
| 200-Day MA | $192.01 |
| Avg Volume | 1.2M |
| Beta | 1.7 |
|
52-Week Range
$125.38
| |
About Natera, Inc. (NTRA)
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Purification Calculator
As a halal stock with 2.55% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Natera, Inc. (NTRA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Natera, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Natera, Inc.'s debt ratio?
Natera, Inc.'s debt ratio is 0.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.3%.
Does Natera, Inc. require dividend purification?
Yes, Natera, Inc. has an impermissible income ratio of 2.55%, which means 2.55% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Natera, Inc.'s key financial metrics?
Natera, Inc. has a market capitalization of $25.9B, and revenue of $2.3B. The company maintains a gross margin of 64.7% and a net margin of -9.0%. Return on equity stands at -14.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.